NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Price, News & Analysis

vTv Therapeutics logo
$17.29 -0.40 (-2.26%)
Closing price 04:00 PM Eastern
Extended Trading
$17.06 -0.23 (-1.33%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About vTv Therapeutics Stock (NASDAQ:VTVT)

Advanced

Key Stats

Today's Range
$16.71
▼
$18.00
50-Day Range
$17.29
▼
$33.29
52-Week Range
$16.71
▼
$44.00
Volume
26,819 shs
Average Volume
22,303 shs
Market Capitalization
$69.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.83
Consensus Rating
Moderate Buy

Company Overview

vTv Therapeutics is a U.S. clinical-stage biopharmaceutical company that discovers and develops small-molecule medicines for serious diseases. Its research has focused on metabolic conditions and other areas of significant medical need.

The company’s candidates have included cadisegliatin, formerly known as TTP399, an oral glucokinase activator studied as an addition to insulin therapy for people with type 1 diabetes, and azeliragon, an investigational compound studied for Alzheimer’s disease. These are development-stage products, not established commercial medicines.

Based in High Point, North Carolina, vTv has advanced its candidates through clinical research rather than marketing a broad range of approved products. Paul Sekhri has served as the company’s president and chief executive officer.

AI Generated. May Contain Errors.

vTv Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

VTVT MarketRank™: 
2.924015382575 of 5 stars

vTv Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 388th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    vTv Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    vTv Therapeutics has a consensus price target of $55.83, representing about 222.9% upside from its current price of $17.29.

  • Amount of Analyst Coverage

    vTv Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about vTv Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for vTv Therapeutics are expected to decrease in the coming year, from ($2.58) to ($3.93) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of vTv Therapeutics is -18.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of vTv Therapeutics is -18.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    vTv Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.93% of the float of vTv Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    vTv Therapeutics has a short interest ratio ("days to cover") of 8.21.
  • Change versus previous month

    Short interest in vTv Therapeutics has recently increased by 1.41%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    vTv Therapeutics does not currently pay a dividend.

  • Dividend Growth

    vTv Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    vTv Therapeutics has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for vTv Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    4 people have added vTv Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, vTv Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.99% of the stock of vTv Therapeutics is held by insiders.

  • Percentage Held by Institutions

    17.51% of the stock of vTv Therapeutics is held by institutions.

  • Read more about vTv Therapeutics' insider trading history.
Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VTVT Stock News Headlines

Comparing vTv Therapeutics (VTVT) and Its Rivals
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
See More Headlines

VTVT Stock Analysis - Frequently Asked Questions

vTv Therapeutics' stock was trading at $39.99 on January 1st, 2026. Since then, VTVT stock has decreased by 56.8% and is now trading at $17.29.

vTv Therapeutics Inc. (NASDAQ:VTVT) issued its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.09) by $0.15.

Shares of vTv Therapeutics reverse split on the morning of Tuesday, November 21st 2023.The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

vTv Therapeutics (VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,812,500 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Top institutional shareholders of vTv Therapeutics include Samsara Biocapital LLC (9.00%), Marshall Wace LLP (0.61%), State Street Corp (0.33%) and China Universal Asset Management Co. Ltd..
View institutional ownership trends
.

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that vTv Therapeutics investors own include NIO (NIO), Nokia (NOK), Sorrento Therapeutics (SRNE), Tesla (TSLA), Micron Technology (MU), Advanced Micro Devices (AMD) and OPKO Health (OPK).

Company Calendar

Last Earnings
11/05/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VTVT
CIK
1641489
Employees
26
Year Founded
1998

Price Target and Rating

High Price Target
$67.00
Low Price Target
$42.00
Potential Upside/Downside
+222.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.97 million
Net Margins
N/A
Pretax Margin
-20.84%
Return on Equity
-10.15%
Return on Assets
-8.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.19
Quick Ratio
11.19

Sales & Book Value

Annual Sales
$1.02 million
Price / Sales
67.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$17.37 per share
Price / Book
1.00

Miscellaneous

Outstanding Shares
4,010,000
Free Float
3,772,000
Market Cap
$69.33 million
Optionable
Not Optionable
Beta
0.28

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:VTVT) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners